Top

Published in:

Open Access 01-08-2011 | Review Article

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

Authors: Mario E. Lacouture, Milan J. Anadkat, René-Jean Bensadoun, Jane Bryce, Alexandre Chan, Joel B. Epstein, Beth Eaby-Sandy, Barbara A. Murphy, MASCC Skin Toxicity Study Group

Published in: Supportive Care in Cancer | Issue 8/2011

Abstract

Background

Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities.

Methods

A multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities.

Results

Prophylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible.

Conclusion

Prevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients’ health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.

Available only for authorised users

Balagula Y, Garbe C, Myskowski P, Hauschild A, Rapoport B, Boers-Doets CB, Lacouture ME (2011) Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol 50:129–146PubMedCrossRef

Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72(3–4):152–159PubMedCrossRef

Somerfield M, Padberg J, Pfister D et al (2000) ASCO clinical practice guidelines: process, progress, pitfalls, and prospects. Classic Papers Curr Comments 4:881–886

Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6(10):803–812PubMedCrossRef

Hassel JC, Kripp M, Al-Batran S, Hofheinz RD (2010) Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie 33(3):94–98PubMedCrossRef

Jatoi A, Dakhil SR, Sloan JA, Kugler JW, Rowland KM Jr, Schaefer PL, Novotny PJ, Wender DB, Gross HM, Loprinzi CL (2010) Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer (in press)

Jatoi A, Thrower A, Sloan JA, Flynn PJ, Wentworth-Hartung NL, Dakhil SR, Mattar BI, Nikcevich DA, Novotny P, Sekulic A, Loprinzi CL (2010) Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist 15(9):1016–1022PubMedCrossRef

Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 113(4):847–853PubMedCrossRef

Scope A, Lieb JA, Dusza SW, Phelan DL, Myskowski PL, Saltz L, Halpern AC (2009) A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 61(4):614–620PubMedCrossRef

10.

Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28(8):1351–1357PubMedCrossRef

11.

Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC (2007) Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25(34):5390–5396PubMedCrossRef

12.

Katzer K, Tietze J, Klein E, Heinemann V, Ruzicka T, Wollenberg A (2010) Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab—a report of 29 patients. Eur J Dermatol 20(1):82–84PubMed

13.

Perez-Soler R, Zou Y, Li T, Tornos C, Ling Y (2006) Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin. J Clin Oncol ASCO Annual Meeting Proceedings part I, vol. 24, no. 18S (June 20 Supplement)

14.

Radovics N, Kornek G, Thalhammer F, Weihsengruber F, Pietrzak C, Resch G, Petzer AL, Hauser I, Wogritsch C, Greil R (2010) Analysis of the effects of vitamin K1 cream on cetuximab-induced acne-like rash. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 28:15S (May 20 Supplement)

15.

Bidoli P, Cortinovis DL, Colombo I, Crippa A, Cicchiello F, Villa F, Cazzaniga ME, Altomare G (2010) Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer. J Thorac Oncol 5(10):1662–1663PubMedCrossRef

16.

Vezzoli P, Marzano AV, Onida F, Alessi E, Galassi B, Tomirotti M, Berti E (2008) Cetuximab-induced acneiform eruption and the response to isotretinoin. Acta Derm Venereol 88(1):84–86PubMedCrossRef

17.

Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J (2005) Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 153(4):849–851PubMedCrossRef

18.

Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, Zhang P, Kohut B (2007) A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 57(5):767–774PubMedCrossRef

19.

Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, Trancik RJ (2002) A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 47(3):377–385PubMedCrossRef

20.

Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, Savin RC, Tharp MD (2004) A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 50(4):541–553PubMedCrossRef

21.

Burtness B, Anadkat M, Basti S et al (2009) NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc 7(S1):s5–s21

22.

Ocvirk J, Cencelj S (2010) Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. JEADV 24:453–459PubMed

23.

Hoffmann R (2008) A 4-month, open-label study evaluating the efficacy of eflornithine 11.5% creamin the treatment of unwanted facial hair in women using TrichoScan. Eur J Dermatol 18(1):65–70PubMed

24.

Jackson J, Caro JJ, Caro G, Garfield F, Huber F, Zhou W, Lin CS, Shander D, Schrode K, Eflornithine HCl Study Group (2007) The effect of eflornithine 13.9% cream on the bother and discomfort due tohirsutism. Int J Dermatol 46(9):976–981PubMedCrossRef

25.

Amin SP, Goldberg DJ (2006) Clinical comparison of four hair removal lasers and light sources. J Cosmet Laser Ther 8(2):65–68PubMedCrossRef

26.

Hamzavi I, Tan E, Shapiro J, Lui H (2007) A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. J Am Acad Dermatol 57(1):54–59PubMedCrossRef

27.

Smith SR, Piacquadio DJ, Beger B, Littler C (2006) Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial. Dermatol Surg 32(10):1237–1243PubMedCrossRef

28.

Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at http://ctep.cancer.gov/forms/CTCAEv3.pdf

29.

Campbell IR, Illingworth MH (1992) Can patients wash during radiotherapy to the breast or chest wall? A randomized controlled trial. Clin Oncol (R Coll Radiol) 4:78–82

30.

Roy I, Fortin A, Larochelle M (2001) The impact of skin washing with water and soap during breast irradiation: a randomized study. Radiother Oncol 58:333–339PubMedCrossRef

31.

Salvo N, Barnes E, van Draanen J, Stacey E, Mitera G, Breen D, Giotis A, Czarnota G, Pang J, De Angelis C (2010) Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature. Curr Oncol 17(4):94–112PubMed

32.

Miller RC, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, Stoffel TJ, Haselow RE, Schaefer PL, Bearden JD 3rd, Atherton PJ, Loprinzi CL, Martenson JA (2010) Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4. Int J Radiat Oncol Biol Phys 79:1460–1466PubMed

33.

Elliott EA, Wright JR, Swann RS et al (2006) Phase III trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13. J Clin Oncol 24:2092–2097PubMedCrossRef

34.

Aygenc E, Celikkanat S, Kaymakci M et al (2004) Prophylactic effect of pentoxifylline on radiotherapy complications: a clinical study. Otolaryngol Head Neck Surg 130:351–356PubMedCrossRef

35.

Lin LC, Que J, Lin LK, Lin FC (2006) Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. Int J Radiat Oncol Biol Phys 65:745–750PubMedCrossRef

36.

Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16:1425–1433PubMedCrossRef

37.

Segaert S, Tabernero J, Chosidow O et al (2005) The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 3:599–606PubMedCrossRef

38.

Roé E, García Muret MP, Marcuello E, Capdevila J, Pallarés C, Alomar A (2006) Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 55:429–437PubMedCrossRef

39.

Racca P, Fanchini L, Caliendo V et al (2008) Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an Oncologic/Dermatologic Cooperation. Clin Colorectal Cancer 7:48–54PubMedCrossRef

40.

Monroe EW, Bernstein DI, Fox RW et al (1992) Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. Arzneimittelforschung 42:1119–1121PubMed

41.

Monroe EW (1992) Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther 14(1):17–21PubMed

42.

Porzio G, Aielli F, Verna L, Porto C, Tudini M, Cannita K, Ficorella C (2006) Efficacy of pregabalin in the management of cetuximab-related itch. J Pain Symptom Manage 32:397–398PubMedCrossRef

43.

Goutos I, Eldardiri M, Khan AA, Dziewulski P, Richardson PM (2010) Comparative evaluation of antipruritic protocols in acute burns. The emerging value of gabapentin in the treatment of burns pruritus. J Burn Care Res 31(1):57–63PubMedCrossRef

44.

Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H (2004) Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 19(12):3137–3139PubMedCrossRef

45.

Vincenzi B, Tonini G, Santini D (2010) Aprepitant for erlotinib-induced pruritus. N Engl J Med 363:397–398PubMedCrossRef

46.

Bromm B, Scharein E, Darsow U, Ring J (1995) Effects of menthol and cold on histamine-induced itch and skin reactions in man. Neurosci Lett 187:157–160PubMedCrossRef

47.

Drake LA, Millikan LE (1995) The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group. Arch Dermatol 131(12):1403–1408PubMedCrossRef

48.

Shohrati M, Davoudi SM, Keshavarz S, Sadr B, Tajik A (2007) Cetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: a randomized clinical trial. Cutan Ocul Toxicol 26(3):249–255PubMedCrossRef

49.

Pour-Reza-Gholi F, Nasrollahi A, Firouzan A, Nasli Esfahani E, Farrokhi F (2007) Low-dose doxepin for treatment of pruritus in patients on hemodialysis. Iran J Kidney Dis 1(1):34–37PubMed

50.

Eschler DC, Klein PA (2010) An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus. J Drugs Dermatol 9(8):992–997PubMed

51.

Yaffe SJ et al (1973) Antihistamine in topical preparations. Pediatrics 51:299–301

52.

Khuntia D, Harris J, Bentzen SM et al (2008) Increased oral mucositis after IMRT versus non-IMRT when combined with cetuximab and cisplatin or docetaxel for head and neck cancer: preliminary results of RTOG 0234. Int J Radiat Oncol Biol Phys 72(1):S33

53.

Motzer RJ, Amato R, Todd M et al (2003) Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21(1):99–101PubMedCrossRef

54.

Xiong HQ, Rosenberg A, LoBuglio A et al (2004) Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 22(13):2610–2616PubMedCrossRef

55.

Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22(7):1201–1208PubMedCrossRef

56.

Reynolds NA, Wagstaff AJ (2004) Cetuximab—in the treatment of metastatic colorectal cancer. Drugs 64(1):109–118PubMedCrossRef

57.

Vermorken JB, Trigo J, Hitt R et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25(16):2171–2177PubMedCrossRef

58.

Belani CP, Schreeder MT, Steis RG et al (2008) Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer 113(9):2512–2517PubMedCrossRef

59.

Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. New Engl J Med 359(11):1116–1127PubMedCrossRef

60.

Thomas M (2005) Cetuximab: adverse event profile and recommendations for toxicitmanagement. Clin J Oncol Nurs 9(3):332–338PubMedCrossRef

61.

Lenz HJ (2006) Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology 20(5 Suppl 2):5–13PubMed

62.

Keefe DM, Schubert MM, Elting LS, St S, Epstein JB, Raber-Drulacher JE et al (2007) Updated clinical practice guidelines for the prevention and treatment of mucostis. Cancer 109(5):820–831PubMedCrossRef

63.

Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9):2026–2046PubMedCrossRef

64.

Epstein JB, Elad S, Eliav E, Jurevic R, Benoliel R (2007) Orofacial pain in cancer: part II: clinical perspectives and management. J Dent Res 86(6):506–518PubMed

65.

Gorsky M, Epstein J, Raviv A, Yaniv R, Truelove E (2008) Topical minocycline for managing symptoms of recurrent aphthous stomatitis. Spec Care Dent 28(1):27–31CrossRef

66.

Gorsky M, Epstein JB, Sl R, Elishoov H, Yarom N (2007) Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study. Dermatol Online J 13(2):1PubMed

67.

Tsimboukis S, Merikas I, Karapanagiotou EM, Saif MW, Syrigos KN (2009) Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer 10(2):106–111PubMedCrossRef

68.

Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW (2007) Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 56(2):317–326PubMedCrossRef

69.

Ricciardi S, Tomao S, de Marinis F (2009) Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10(1):28–35PubMedCrossRef

70.

Saif MW, Kaley K, Lamb L, Pecerillo J, Hotchkiss S, Steven L, Brennan M, Penney R, Gillespie C, Shaib W (2010) Management of skin toxicities of anti-EGFR agents in patients with pancreatic cancer and other GI tumors by using electronic communication: effective and convenient. JOP 11(2):176–182PubMed

71.

Gutzmer R, Werfel T, Kapp A, Elsner J (2006) Cutaneous side effects of EGF-receptor inhibition and their management. Hautarzt 57(6):509–513PubMedCrossRef

72.

Pérez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulières D, Saltz L, Leyden J (2005) HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10(5):345–356PubMedCrossRef

73.

Wollenberg A, Kroth J, Hauschild A, Dirschka T (2010) Cutaneous side effects of EGFR inhibitors—appearance and management. Dtsch Med Wochenschr 135(4):149–154PubMedCrossRef

74.

Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, Ben-Porat L, Sachs DL, Heelan RT, Miller VA (2005) Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 23(1):165–174PubMed

75.

Jennings MB, Alfieri D, Ward K, Lesczczynski C (1998) Comparison of salicylic acid and urea versus ammonium lactate for the treatment of foot xerosis. A randomized, double-blind, clinical study. J Am Podiatr Med Assoc 88(7):332–336PubMed

76.

Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144(6):1169–1176PubMedCrossRef

77.

Becker A, van Wijk A, Smit EF, Postmus PE (2010) Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer. J Thorac Oncol 5(9):1477–1480PubMedCrossRef

78.

OSI Pharmaceuticals (2005) Tarceva package insert

79.

ImClone Systems (2006) Erbitux package insert

80.

Osio A, Mateus C, Soria JC, Massard C, Malka D, Boige V, Besse B, Robert C (2009) Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 161(3):515–521PubMedCrossRef

81.

Hong SH, Wong CW, Privalsky ML (1998) Signaling by tyrosine kinases negatively regulates the interaction between transcription factors and SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) corepressor. Mol Endocrinol 12:1161–1171PubMedCrossRef

82.

Baran R (1986) Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects. Clin Exp Dermatol 11:148–152PubMedCrossRef

83.

Bouscarat F, Bouchard C, Bouhour D (1998) Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir. N Engl J Med 338:1776–1777PubMedCrossRef

84.

Sassone LM, Fidel RA, Murad CF, Fidel SR, Hirata R Jr (2008) Antimicrobial activity of sodium hypochlorite and chlorhexidine by two different tests. Aust Endod J 34(1):19–24PubMedCrossRef

85.

Eames T, Grabein B, Kroth J, Wollenberg A (2010) Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. J Eur Acad Dermatol Venereol 24(8):958–960PubMed

86.

Floersheim GL (1989) Treatment of brittle fingernails with biotin. Z Hautkr 64(1):41–48PubMed

87.

Tosti A, Piraccini BM, Ghetti E, Colombo MD (2002) Topical steroids versus systemic antifungals in the treatment of chronic paronychia: an open, randomized double-blind and double dummy study. J Am Acad Dermatol 47(1):73–76PubMedCrossRef

88.

Wollina U (2001) Acute paronychia: comparative treatment with topical antibiotic alone or in combination with corticosteroid. J Eur Acad Dermatol Venereol 15(1):82–84PubMedCrossRef

89.

Rao A, Bunker C (2010) Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. Br J Dermatol 163(1):208PubMed

90.

Rigopoulos D, Gregoriou S, Belyayeva E, Larios G, Ontochristopoulos G, Katsambas A (2009) Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. Br J Dermatol 160(4):858–860PubMedCrossRef

91.

Daniel CR 3rd, Daniel MP, Daniel CM, Sullivan S, Ellis G (1996) Chronic paronychia and onycholysis: a thirteen-year experience. Cutis 58:397–401PubMed

92.

Rosenbaum D, Merenstein D, Meyer F (2002) Topical steroids more effective than antifungals for chronic paronychia. J Fam Pract 51:824PubMed

93.

Roberts DT, Richardson MD, Dwyer PK, Donegan R (1992) Terbinafine in chronic paronychia and candida onychomycosis. J Derm Treat S1:39–42CrossRef

94.

Rutala WA, Weber DJ (1997) Uses of inorganic hypochlorite (bleach) in health-care facilities. Clin Microbiol Rev 10(4):597–610PubMed

95.

Shu KY, Kindler HL, Medenica M, Lacouture M (2006) Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol 154(1):191–192PubMed

96.

Wilhelmi BJ, Calianos TA II, Appelt EA, Ortiz ME, Heggers JP, Phillips LG (1999) Modified Dakin’s solution for cutaneous vibrio infections. Ann Plast Surg 43(4):386–389PubMedCrossRef

97.

Rutala WA, Cole EC, Thomann CA, Weber DJ (1998) Stability and bactericidal activity of chlorine solutions. Infect Control Hosp Epidemiol 19(5):323–327PubMedCrossRef

98.

Quitkin HM, Rosenwasser MP, Strauch RJ (2003) The efficacy of silver nitrate cauterization for pyogenic granuloma of the hand. J Hand Surg Am 28(3):435–438PubMedCrossRef

99.

Ghodsi SZ, Raziei M, Taheri A, Karami M, Mansoori P, Farnaghi F (2006) Comparison of cryotherapy and curettage for the treatment of pyogenic granuloma: a randomized trial. Br J Dermatol 154(4):671–675PubMed

100.

Saltz L, Rubin MS, Hochster H et al (2001) Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor. Clin Cancer Res 7:3766s (abstract 559)

101.

Bentzen SM, Trotti A (2007) Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 25(26):4096–4103PubMedCrossRef

102.

Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26(3):374–379PubMedCrossRef

103.

Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluropyrimidines. J Clin Oncol 24(30):4814–4921

104.

Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22(1):77–85PubMed

105.

Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA (2007) Phase II clinical trial of chemotherapy-naive patients ≥70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 29(7):760–766CrossRef

106.

West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, Gandara DR (2006) Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 24(12):1807–1813PubMedCrossRef

107.

Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE (2005) Phase II trial of gefitinib 250 mg po daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 11(23):8418–8424PubMedCrossRef

108.

Meropol NJ, Berlin J, Hecht JR et al (2003) Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 22:256

109.

Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22(16):3238–3247PubMedCrossRef

110.

Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol 22(5):785–794PubMedCrossRef

111.

Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18:509–522PubMedCrossRef

112.

MASCC EGFR Inhibitor Skin Toxicity Tool (MESTT). Available at http://www.mascc.org/mc/page.do?sitePageId=98483

113.

NCI Common Terminology Criteria for Adverse Events v4.03 (CTCAE). Available at http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf

114.

Chan A, Tan EH (2010) How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Support Care Cancer (in press)

Title: Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
Authors: Mario E. Lacouture
Milan J. Anadkat
René-Jean Bensadoun
Jane Bryce
Alexandre Chan
Joel B. Epstein
Beth Eaby-Sandy
Barbara A. Murphy
MASCC Skin Toxicity Study Group
Publication date: 01-08-2011
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 8/2011
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-011-1197-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2011

Improving the availability and accessibility of opioids for the treatment of pain: The International Pain Policy Fellowship

Measuring perceived benefit and disease-related burden in young cancer survivors: validation of the Benefit and Burden Scale for Children (BBSC) in the Netherlands

Decisions for lung cancer chemotherapy: the influence of physician and patient factors

Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial

The initial development of an instrument to assess the psychosocial needs and unmet needs of young people who have a parent with cancer: piloting the offspring cancer needs instrument (OCNI)

Effect of saliva substitutes in combination with fluorides on remineralization of subsurface dentin lesions

Keynote webinar | Spotlight on antibody–drug conjugates in cancer